Trial Profile
Study of 23-valent pneumococcal polysaccharide vaccine and influenza vaccine against pneumococcal pneumonia among elderly patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2018
Price :
$35
*
At a glance
- Drugs Pneumococcal 23-valent vaccine Walvax Biotechnology (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- 12 Nov 2018 New trial record
- 07 Oct 2018 Results presented at the IDWeek 2018